Microorganism introduced with foreign glutamine synthetase and method of producing l-tryptophan using the same
Patent Information
- Application Number
- MYPI2025003942
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-28
- Filing Date
- 2023-12-28
- Publication Date
- 2024-06-28
AI Technical Summary
Current methods for producing L-tryptophan in microorganisms are limited in terms of production capacity, necessitating the development of more efficient approaches to increase yield.
Introduction of a foreign glnA protein or polynucleotide encoding glutamine synthetase into Corynebacterium microorganisms, enhancing their glutamine synthetase activity to increase L-tryptophan production.
The enhanced glutamine synthetase activity in microorganisms leads to increased L-tryptophan production capacity, improving fermentation yields by up to 25% compared to unmodified strains.
Abstract
Description
Microorganisms with introduced foreign glutamine synthetase and methods for producing L-tryptophan using the same
[0001] The present application relates to a microorganism into which an exogenous glutamine synthetase has been introduced and a method for producing L-tryptophan using the same.
[0002]
[0003] To produce L-amino acids and other useful substances, various studies are being conducted to develop high-efficiency production microorganisms and fermentation process technologies. For example, when producing L-tryptophan, target-substance-specific approaches are primarily used, such as increasing the expression of genes encoding enzymes involved in L-tryptophan biosynthesis or removing genes unnecessary for biosynthesis (US 8,945,907 B2).
[0004] However, due to the increasing demand for L-tryptophan, research is still needed to effectively increase the production of L-tryptophan.
[0005]
[0006] The present inventors completed the present application by confirming that when an exogenous glnA protein is introduced into a microorganism, L-tryptophan production ability is increased compared to an unmodified microorganism.
[0007]
[0008] The present application provides a microorganism of the genus Corynebacterium into which a foreign glnA protein or a polynucleotide encoding the same has been introduced.
[0009] The present application provides a method for producing L-tryptophan, comprising a step of culturing a microorganism of the genus Corynebacterium into which a foreign glnA protein or a polynucleotide encoding the same has been introduced in a medium.
[0010] The present application provides a composition for producing L-tryptophan, comprising a Corynebacterium microorganism into which an exogenous glnA protein or a polynucleotide encoding the same has been introduced; a medium in which the same has been cultured; or a combination thereof.
[0011]
[0012] The microorganism of the present application can have increased L-tryptophan production ability compared to an existing unmodified microorganism by introducing a foreign glnA protein.
[0013]
[0014] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below. Furthermore, numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated into this specification in their entirety by reference to more clearly explain the level of the technical field to which this application belongs and the contents of this application.
[0015]
[0016] One aspect of the present application provides a microorganism of the genus Corynebacterium into which an exogenous glnA protein or a polynucleotide encoding the same has been introduced.
[0017]
[0018] In the present application, the term "glutamine synthetase (glnA)" refers to a protein having the activity of biosynthesizing glutamine from glutamic acid and ammonia. The term "glutamine synthetase" may be used interchangeably with "glnA protein", "glnA", etc. In addition, it may be a protein having the activity of biosynthesizing glutamine from glutamic acid and ammonia, also called "glutamate-ammonia ligase."
[0019] The amino acid sequence of the above glnA protein can be obtained from a known database such as NCBI's Genbank.
[0020] For example, the glnA protein of the present application may be derived from a microorganism. Specifically, the protein may be derived from a microorganism selected from the genus Aureibacillus, Caryophanon, and Peribacillus, and more specifically, may be derived from a microorganism selected from Aureibacillus halotolerans, Caryophanon tenue, and Peribacillus simplex, but is not limited thereto.
[0021] As another example, the amino acid sequence of the glnA protein of the present application may be WP_133580410.1 (GenBank accession number) from Ayureibacillus halotolerans, WP_066543527.1 (GenBank accession number) from Caryophanon tenue, and WP_063236399.1 (GenBank accession number) from Peribacillus simplex.
[0022]
[0023] In the present application, the glnA protein may have, include, consist of, or consist essentially of an amino acid sequence of any one of SEQ ID NOs: 1, 3, and 5.
[0024] In the present application, the glnA protein may include an amino acid sequence of any one of SEQ ID NOs: 1, 3, and 5, or an amino acid sequence having at least 70%, 75%, 76%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, or 99.9% homology or identity thereto. For example, the glnA protein of the present application may include at least one selected from the group consisting of an amino acid sequence of any one of SEQ ID NOs: 1, 3, and 5, or an amino acid sequence having at least 90% homology or identity thereto. In addition, it is obvious that a protein having an amino acid sequence in which some of the sequences are deleted, modified, substituted, conservatively substituted or added is also included within the scope of the present application, provided that the amino acid sequence exhibits an effect corresponding to a protein having such homology or identity and comprising any one of the amino acid sequences of SEQ ID NOs: 1, 3 and 5.
[0025] For example, if the amino acid sequence has sequence additions or deletions, naturally occurring mutations, silent mutations or conservative substitutions that do not alter the function of the protein of the present application at the N-terminus, C-terminus and / or within the amino acid sequence.
[0026] The term "conservative substitution" refers to the replacement of one amino acid with another amino acid having similar structural and / or chemical properties. Such amino acid substitutions may generally be based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. Typically, conservative substitutions may have little or no effect on the activity of a protein or polypeptide.
[0027]
[0028] In this application, the terms "homology" or "identity" refer to the degree of similarity between two given amino acid sequences or base sequences, which may be expressed as a percentage. The terms "homology" and "identity" are often used interchangeably.
[0029] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences can generally hybridize with all or part of the sequence under moderate or high stringency conditions. It should be appreciated that hybridization also includes hybridization with polynucleotides containing common codons or codons that take codon degeneracy into account.
[0030] Whether any two polynucleotide or polypeptide sequences are homologous, similar or identical can be determined using known computer algorithms such as the "FASTA" program using default parameters, for example, as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO ET AL.](1988) SIAM J Applied Math 48: 1073). For example, homology, similarity, or identity can be determined using BLAST or ClustalW of the National Center for Biotechnology Information Database.
[0031] Homology, similarity, or identity of polynucleotides or polypeptides can be determined by comparing sequence information, for example, using a GAP computer program such as that of Needleman et al. (1970), J Mol Biol. 48:443, as disclosed, for example, in Smith and Waterman, Adv. Appl. Math (1981) 2:482. In brief, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). Default parameters for the GAP program are (1) a unitary matrix (containing values of 1 for identity and 0 for non-identity) and (2) a matrix of 1 and 0 for identity, as disclosed by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979), Gribskov et al. (1986) Nucl. Acids Res. 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) permutation matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10 and a gap extension penalty of 0.5); and (3) no penalty for terminal gaps.
[0032]
[0033] The glnA protein of the present application may be encoded by the glnA gene.
[0034] As an example, the glnA gene may be a polynucleotide encoding WP_133580410.1 from Ayureibacillus halotolerans, WP_066543527.1 from Caryophanon tenue, or WP_063236399.1 from Peribacillus simplex, but is not limited thereto. As another example, the glnA gene may be NZ_SNYJ01000007.1 from Ayureibacillus halotolerans, NZ_MASJ01000003.1 from Caryophanon tenue, or NZ_CP017704.1 from Peribacillus simplex, but is not limited thereto, and it is apparent that various derived glnA genes encoding proteins having glutamine synthetase activity are included.
[0035] In this application, the term "polynucleotide" means a polymer of nucleotides in which nucleotide units (monomers) are covalently bonded to form a long chain, a DNA or RNA strand of a certain length or longer, and more specifically, a polynucleotide fragment that encodes the protein.
[0036] The polynucleotide encoding the glnA protein of the present application may include a base sequence encoding an amino acid sequence of any one of SEQ ID NOs: 1, 3, and 5. As an example of the present application, the polynucleotide of the present application may have or include a base sequence of any one of SEQ ID NOs: 2, 4, and 6. In addition, the polynucleotide of the present application may consist of, or consist essentially of, a base sequence of any one of SEQ ID NOs: 2, 4, and 6. Specifically, the glnA gene may be encoded by a polynucleotide described by a base sequence of any one of SEQ ID NOs: 2, 4, and 6.
[0037] The polynucleotide of the present application may have various modifications made to the coding region within a range that does not change the amino acid sequence of the glutamine synthetase, taking into account the degeneracy of the codon or the codon preferred in the organism that is intended to express the glutamine synthetase of the present application. Specifically, the polynucleotide of the present application has or includes a base sequence having at least 70%, at least 75%, at least 76%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology or identity with any one of SEQ ID NOs: 2, 4, and 6, or may consist of or consist essentially of a base sequence having at least 70%, at least 75%, at least 76%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology or identity with any one of SEQ ID NOs: 2, 4, and 6, but is not limited thereto.
[0038] In addition, the polynucleotide of the present application may include, without limitation, a probe that can be prepared from a known genetic sequence, for example, a sequence that can hybridize under stringent conditions with a complementary sequence to all or part of the polynucleotide sequence of the present application. The term "stringent conditions" refers to conditions that enable specific hybridization between polynucleotides. Such conditions are specifically described in the literature (see J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; FM Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, 9.50-9.51, 11.7-11.8). For example, conditions in which polynucleotides having high homology or identity hybridize with each other, polynucleotides having 70% or more, 75% or more, 76% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology or identity hybridize with each other, and polynucleotides having lower homology or identity do not hybridize with each other, or conditions in which washing is performed once, specifically twice or three times, at a salt concentration and temperature equivalent to 60°C, 1ХSSC, 0.1% SDS, specifically 60°C, 0.1ХSSC, 0.1% SDS, and more specifically 68°C, 0.1ХSSC, 0.1% SDS, which are washing conditions of typical southern hybridization, are performed.
[0039] Hybridization requires that two nucleic acids have complementary sequences, although mismatches between bases are possible depending on the stringency of hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenine is complementary to thymine, and cytosine is complementary to guanine. Therefore, the polynucleotides of the present application may also include isolated nucleic acid fragments that are complementary in their entirety, as well as substantially similar nucleic acid sequences.
[0040] Specifically, a polynucleotide having homology or identity with the polynucleotide of the present application can be detected using hybridization conditions including a hybridization step at a Tm value of 55°C and using the conditions described above. In addition, the Tm value may be, but is not limited to, 60°C, 63°C, or 65°C, and can be appropriately adjusted by a person skilled in the art depending on the purpose.
[0041] The appropriate stringency for hybridizing the polynucleotides depends on the length and degree of complementarity of the polynucleotides, variables which are well known in the art (e.g., J. Sambrook et al., supra).
[0042]
[0043] In this application, the term "microorganism (or strain)" includes both wild-type microorganisms and microorganisms that have undergone genetic modification naturally or artificially, and may be a microorganism that has a specific mechanism strengthened or weakened due to causes such as the insertion of an external gene or the strengthening or weakening of the activity of an endogenous gene, and may be a microorganism that includes genetic modification for the production of a desired polypeptide, protein or product.
[0044] Accordingly, examples of the microorganism of the present application include a recombinant microorganism into which an exogenous glnA protein having increased glutamine synthetase activity is introduced compared to a wild-type Corynebacterium genus microorganism and / or a recombinant microorganism having a genetic modification such that the activity of the glnA protein is enhanced compared to the endogenous activity.
[0045] The microorganism of the present invention may have enhanced glnA protein activity compared to its endogenous activity. For example, the microorganism may be a microorganism with enhanced L-tryptophan production by introducing the activity of an exogenous glnA protein. The microorganism may have enhanced glnA protein activity by introducing the activity of an exogenous glnA protein that is not endogenously expressed.
[0046] The enhanced activity of the glnA protein may indicate that the glnA protein, which is not endogenously expressed, has been introduced, and thus exhibits the activity of an exogenous glnA protein that was not originally present. Alternatively, the enhanced activity of the glnA protein may indicate increased activity compared to the endogenous glnA protein.
[0047] For example, the microorganism of the present application may have enhanced glutamine synthetase activity within the microorganism by introducing an exogenous glnA protein having increased glutamine synthetase activity compared to a wild-type Corynebacterium microorganism, but is not limited thereto.
[0048]
[0049] In this application, the term "enhancement" of a polypeptide (including, for example, a protein specified by the name of each enzyme) means that the activity of the polypeptide is increased compared to the intrinsic activity. The term "enhancement" may be used interchangeably with terms such as activation, up-regulation, overexpression, and increase. Here, activation, enhancement, up-regulation, overexpression, and increase may all include exhibiting an activity that was not originally present, or exhibiting an activity that is enhanced compared to the intrinsic activity or the activity before modification. The "intrinsic activity" refers to the activity of a specific polypeptide that a parent strain or an unmodified microorganism originally possessed before the trait change, when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with "pre-modification activity." "Enhanced," "upregulated," "overexpressed," or "increased" the activity of a polypeptide relative to its intrinsic activity means that the activity and / or concentration (expression amount) of the specific polypeptide is improved compared to the activity and / or concentration (expression amount) that the parent strain or unmodified microorganism originally had prior to the transformation.
[0050] The above enhancement can be achieved by introducing an exogenous polypeptide, or by enhancing the activity and / or concentration (expression level) of an endogenous polypeptide. Whether the activity of the polypeptide is enhanced can be determined by an increase in the level of activity, expression level, or amount of product excreted from the polypeptide.
[0051] For the purpose of the present application, the microorganism of the present application has an enhanced L-tryptophan production ability by introducing an exogenous glnA protein having increased glutamine synthetase activity compared to a wild-type Corynebacterium microorganism, thereby enhancing glutamine synthetase activity in the microorganism. The target strain for comparing whether the L-tryptophan production ability or glutamine synthetase activity is increased, which is an unmodified microorganism without an exogenous glnA protein introduced, may be, but is not limited to, the CM05-9157 strain (US 2023-0134555 A1), which is an L-tryptophan producing strain, and the CM05-9157 strain into which the wild-type Corynebacterium glutamicum-derived glnA protein is introduced.
[0052] Enhancement of the activity of the above polypeptide can be achieved by applying various methods well known in the art, and is not limited as long as the activity of the target polypeptide can be enhanced compared to that of the microorganism before modification. Specifically, it may be achieved by using genetic engineering and / or protein engineering, which are routine methods of molecular biology and are well known to those skilled in the art, but is not limited thereto (e.g., Sitnicka et al. Functional Analysis of Genes. Advances in Cell Biology. 2010, Vol. 2. 1-16, Sambrook et al. Molecular Cloning 2012, etc.).
[0053] Specifically, the enhancement of the activity of the polypeptide of the present application is
[0054] 1) Increase in the intracellular copy number of a polynucleotide encoding a polypeptide;
[0055] 2) Replacing the gene expression control region on the chromosome encoding the polypeptide with a highly active sequence;
[0056] 3) Modification of the base sequence encoding the initiation codon or 5'-UTR region of a gene transcript encoding a polypeptide;
[0057] 4) Modification of the amino acid sequence of the polypeptide so as to enhance polypeptide activity;
[0058] 5) Modification of the polynucleotide sequence encoding the polypeptide so as to enhance the activity of the polypeptide (e.g., modification of the polynucleotide sequence of the polypeptide gene so as to encode a polypeptide modified so as to enhance the activity of the polypeptide);
[0059] 6) Introduction of a foreign polypeptide exhibiting the activity of the polypeptide or a foreign polynucleotide encoding the same;
[0060] 7) Codon optimization of a polynucleotide encoding a polypeptide;
[0061] 8) Analyzing the tertiary structure of the polypeptide and selecting the exposed portion to modify or chemically modify; or
[0062] 9) It may be a combination of two or more of the above 1) to 8), but is not particularly limited thereto.
[0063] More specifically,
[0064] The increase in the intracellular copy number of the polynucleotide encoding the polypeptide described above may be achieved by introducing into the host cell a vector capable of replicating and functioning independently of the host, to which the polynucleotide encoding the polypeptide is operably linked. Alternatively, the polynucleotide encoding the polypeptide may be achieved by introducing one copy or two or more copies into the chromosome of the host cell. The introduction into the chromosome may be performed by introducing into the host cell a vector capable of inserting the polynucleotide into the chromosome of the host cell, but is not limited thereto. The vector is as described above.
[0065] 2) Replacing the gene expression control region (or expression control sequence) on the chromosome encoding the polypeptide with a sequence having strong activity may be, for example, a mutation in the sequence such as deletion, insertion, non-conservative or conservative substitution, or a combination thereof to further enhance the activity of the expression control region, or replacement with a sequence having stronger activity. The expression control region may include, but is not particularly limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation. As an example, it may be, but is not limited to, replacing the original promoter with a strong promoter.
[0066] Examples of known strong promoters include, but are not limited to, the PlysCm1 promoter (US 2023-0134555 A1), the CJ1 to CJ7 promoters (US Patent No. US 7662943 B2), the lac promoter, the trp promoter, the trc promoter, the tac promoter, the lambda phage PR promoter, the PL promoter, the tet promoter, the gapA promoter, the SPL7 promoter, the SPL13 (sm3) promoter (US Patent No. US 10584338 B2), the O2 promoter (US Patent No. US 10273491 B2), the tkt promoter, and the yccA promoter.
[0067] The above 3) modification of the base sequence encoding the initiation codon or 5'-UTR region of the gene transcript encoding the polypeptide may be, for example, a substitution with a base sequence encoding another initiation codon having a higher polypeptide expression rate than the endogenous initiation codon, but is not limited thereto.
[0068] The modification of the amino acid sequence or polynucleotide sequence of the above 4) and 5) may be, but is not limited to, a mutation in the sequence by deletion, insertion, non-conservative or conservative substitution or a combination thereof in the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide to enhance the activity of the polypeptide, or replacement with an amino acid sequence or polynucleotide sequence improved to have stronger activity or an amino acid sequence or polynucleotide sequence improved to have increased activity. The replacement may be specifically performed by inserting the polynucleotide into a chromosome by homologous recombination, but is not limited thereto. The vector used at this time may additionally include a selection marker to confirm whether or not chromosomal insertion has occurred.
[0069] The introduction of the foreign polynucleotide exhibiting the activity of the polypeptide as described above 6) may be the introduction into the host cell of a foreign polynucleotide encoding a polypeptide exhibiting the same / similar activity as the polypeptide. The foreign polynucleotide is not limited in its origin or sequence as long as it exhibits the same / similar activity as the polypeptide. The method used for the introduction may be performed by a person skilled in the art by appropriately selecting a known transformation method, and the polypeptide may be produced by expressing the introduced polynucleotide in the host cell, thereby increasing its activity.
[0070] The above 7) codon optimization of a polynucleotide encoding a polypeptide may be codon optimization of an endogenous polynucleotide to increase transcription or translation within a host cell, or codon optimization of a foreign polynucleotide to achieve optimized transcription or translation within a host cell.
[0071] The above 8) analyzing the tertiary structure of a polypeptide and selecting an exposed portion to modify or chemically modify may be done by, for example, comparing the sequence information of the polypeptide to be analyzed with a database storing the sequence information of known proteins, determining a template protein candidate based on the degree of sequence similarity, confirming the structure based on this, and selecting an exposed portion to modify or chemically modify, and modifying or modifying it.
[0072] Such enhancement of polypeptide activity may be, but is not limited to, an increase in the activity or concentration or expression level of the corresponding polypeptide relative to the activity or concentration of the polypeptide expressed in the wild type or pre-transformed microbial strain, or an increase in the amount of a product produced from the polypeptide.
[0073] For example, the enhancement of glutamine synthetase activity of the present application may be enhancement by introduction of an exogenous polynucleotide exhibiting glutamine synthetase activity. As another example, the enhancement of glutamine synthetase activity of the present application may be enhancement by replacement of the promoter of a gene encoding glutamine synthetase or enhancement by modification of the promoter. As another example, the enhancement of glutamine synthetase activity of the present application may be enhancement by modification of the base sequence encoding the start codon of a gene transcript encoding glutamine synthetase. As another example, the enhancement may be a combination of the above modifications. However, the present invention is not limited thereto.
[0074]
[0075] In the microorganism of the present application, modification of part or all of the polynucleotide may be induced by, but is not limited to, (a) homologous recombination using a vector for chromosome insertion into the microorganism or genome editing using engineered nucleases (e.g., CRISPR-Cas9) and / or (b) treatment with light and / or chemicals such as ultraviolet rays and radiation. The method for modifying part or all of the gene may include a method using DNA recombination technology. For example, a nucleotide sequence or vector containing a nucleotide sequence homologous to a target gene may be injected into the microorganism to cause homologous recombination, thereby causing deletion of part or all of the gene. The injected nucleotide sequence or vector may include, but is not limited to, a dominant selection marker.
[0076]
[0077] The vector of the present application may comprise a DNA construct comprising a base sequence of a polynucleotide encoding a target polypeptide operably linked to a suitable expression control region (or expression control sequence) so as to enable expression of the target polypeptide in a suitable host. The expression control region may comprise a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and sequences regulating the termination of transcription and translation. The vector may be capable of replicating or functioning independently of the host genome after being transformed into a suitable host cell, or may be integrated into the genome itself.
[0078] The vector used in the present application is not particularly limited, and any vector known in the art can be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A can be used as phage vectors or cosmid vectors, and pDZ series, pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, and pET series can be used as plasmid vectors. Specifically, pDZ, pDC, pDCM2, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors can be used.
[0079] For example, a polynucleotide encoding a target polypeptide can be inserted into a chromosome via a vector for intracellular chromosomal insertion. The insertion of the polynucleotide into the chromosome can be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto. A selection marker for confirming the chromosomal insertion can be additionally included. The selection marker is used to select cells transformed with the vector, i.e., to confirm the insertion of the target nucleic acid molecule. Markers that confer a selectable phenotype, such as drug resistance, nutrient requirement, cytotoxic agent resistance, or expression of a surface polypeptide, can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or exhibit other phenotypic traits, so that transformed cells can be selected.
[0080] The term "transformation" in this application refers to introducing a vector containing a polynucleotide encoding a target polypeptide into a host cell or microorganism so that the polypeptide encoded by the polynucleotide can be expressed in the host cell. The transformed polynucleotide may be located within the chromosome of the host cell or outside the chromosome, as long as it can be expressed in the host cell. In addition, the polynucleotide includes DNA and / or RNA encoding the target polypeptide. The polynucleotide may be introduced in any form as long as it can be introduced into the host cell and expressed. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a genetic construct containing all elements necessary for autonomous expression. The expression cassette may typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal, all of which are operably linked to the polynucleotide. The above expression cassette may be in the form of a self-replicating expression vector. Furthermore, the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not limited thereto.
[0081] Additionally, the term "operably linked" as used herein means that the polynucleotide sequence is functionally linked to a promoter sequence that initiates and mediates transcription of the polynucleotide encoding the target polypeptide of the present application.
[0082]
[0083] As another example of the present application, the microorganism of the present application may be a microorganism having L-tryptophan production ability.
[0084] The microorganism of the present application may be a microorganism with improved L-tryptophan production ability.
[0085]
[0086] The microorganism of the present application may have enhanced glutamine synthetase activity. Specifically, the microorganism of the present application may be a microorganism having an enhanced exogenous glnA protein or a glnA gene encoding the same; or a microorganism genetically modified to further enhance the exogenous glnA protein or the glnA gene encoding the same, but is not limited thereto. The microorganism having an enhanced exogenous glnA protein or the glnA gene encoding the same may have increased glutamine synthetase activity compared to a wild-type or pre-modified Corynebacterium microorganism. For example, the microorganism of the present application may be a recombinant microorganism.
[0087] The microorganism of the present application may be a microorganism that naturally has L-tryptophan production ability or a microorganism in which L-tryptophan production ability is increased or granted by introducing a foreign glnA protein or a polynucleotide encoding the same into a parent strain that does not have L-tryptophan production ability, but is not limited thereto.
[0088] For the purpose of the present application, the recombinant microorganism of the present application may be a microorganism having increased L-tryptophan productivity compared to the naturally occurring wild-type microorganism or the microorganism producing L-tryptophan, including a protein having endogenous glutamine synthetase activity or a polynucleotide encoding the same, by introducing the exogenous glnA protein or a polynucleotide encoding the same into the naturally occurring wild-type microorganism or the microorganism producing L-tryptophan, including a protein having endogenous glutamine synthetase activity or a polynucleotide encoding the same, but is not limited thereto. For example, the naturally occurring wild-type microorganism or the microorganism producing L-tryptophan, including a protein having endogenous glutamine synthetase activity or a polynucleotide encoding the same, may be a target strain for comparing whether the L-tryptophan productivity or glutamine synthetase activity increases as described above, but is not limited thereto.
[0089] For example, the recombinant strain with increased productivity may have an L-tryptophan productivity of about 1% or more, specifically, about 2% or more, about 5% or more, about 7.5% or more, about 10% or more, about 12.5% or more, about 15% or more, about 17.5% or more, about 20% or more, about 21% or more, about 22% or more, about 23% or more, about 24% or more, or about 25% or more (the upper limit is not particularly limited, and may be, for example, about 200% or less, about 150% or less, about 100% or less, about 50% or less, about 40% or less, about 30% or less, about 20% or less, or about 15% or less) increased compared to the L-tryptophan productivity of the parent strain or the non-modified microorganism before mutation, but is not limited thereto as long as it has a positive value increase compared to the productivity of the parent strain or the non-modified microorganism before mutation. In another example, the microorganism with increased productivity may have an L-tryptophan productivity increased by about 1.01 times or more, about 1.02 times or more, about 1.05 times or more, about 1.075 times or more, about 1.1 times or more, about 1.125 times or more, about 1.15 times or more, about 1.175 times or more, about 1.2 times or more, about 1.21 times or more, about 1.22 times or more, about 1.23 times or more, about 1.24 times or more, or about 1.25 times or more (the upper limit is not particularly limited and may be, for example, about 10 times or less, about 5 times or less, about 3 times or less, or about 2 times or less) compared to the parent strain before mutation or the unmodified microorganism, but is not limited thereto.
[0090] This productivity can be evaluated by measuring the production amount of the target product obtained by culturing in a medium. The evaluation can be performed by measuring the production amount of the target product using a suitable method known in the art. For example, HPLC (High Performance Liquid Chromatography), GC (Gas Chromatography), GC / MS (Gas Chromatography-Mass Spectrometry), LC / MS (Liquid chromatography-mass spectrometry), GPC (Gel Permeation Chromatography), or a combination of these methods can be used, and the production amount of the target product can be measured using a suitable method known in the art.
[0091] In this application, the term "unmodified microorganism" does not exclude a strain that contains a mutation that can occur naturally in a microorganism, and may refer to a wild-type strain or a natural strain itself, or a strain before its characteristics are changed by genetic mutation caused by natural or artificial factors. For example, the unmodified microorganism may refer to a strain in which the glutamine synthetase described herein or a polynucleotide encoding it is not enhanced or before it is enhanced. The "unmodified microorganism" may be used interchangeably with "pre-modified strain," "pre-modified microorganism," "unmutated strain," "unmodified microorganism," or "reference microorganism."
[0092]
[0093] In another example of the present application, the microorganism of the present application is Corynebacterium glutamicum, Corynebacterium stationis, Corynebacterium crudilactis, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium callunae, Corynebacterium singulare, Corynebacterium halotolerans, Corynebacterium striatum, Corynebacterium ammoniagenes, Corynebacterium It may be Corynebacterium pollutisoli, Corynebacterium imitans, Corynebacterium testudinoris or Corynebacterium flavescens, and specifically, but not limited to, Corynebacterium glutamicum.
[0094]
[0095] As another example of the present application, the recombinant microorganism of the present application may be a microorganism with enhanced L-tryptophan production ability by further enhancing the activity of a portion of a protein in the L-tryptophan biosynthesis pathway or by further weakening the activity of a portion of a protein in the L-tryptophan degradation pathway.
[0096] In one embodiment, the recombinant microorganism of the present application may be a microorganism in which the activity of a gene of a competitive pathway, a regulator of a directional pathway of the L-tryptophan operon, an L-tryptophan import gene, an L-tryptophan import and degradation gene is weakened or inactivated, and / or the activity of the L-tryptophan operon is overexpressed, in order to strengthen the L-tryptophan biosynthesis pathway.
[0097] In another embodiment, the microorganism may be one in which the activity of a regulatory gene (trpR) of the tryptophan synthetase family that suppresses the expression of L-tryptophan biosynthetic genes (e.g., trpEDCBA), or the activity of a membrane protein (Mtr) that imports L-tryptophan from outside the cell into the cell is weakened or eliminated compared to the endogenous activity. However, the present invention is not limited thereto.
[0098]
[0099] In this application, the term "attenuation" of the activity of a polypeptide encompasses both a decrease in activity or the absence of activity compared to the intrinsic activity. The term "attenuation" may be used interchangeably with terms such as inactivation, deficiency, down-regulation, decrease, reduce, and attenuation.
[0100] The above weakening may also include cases where the activity of the polypeptide itself is reduced or eliminated compared to the activity of the polypeptide originally possessed by the microorganism due to mutation of the polynucleotide encoding the polypeptide, etc., cases where the overall polypeptide activity level and / or concentration (expression amount) within the cell is lower than that of the natural strain due to inhibition of expression of the gene of the polynucleotide encoding the polypeptide or inhibition of translation into a polypeptide, cases where the polynucleotide is not expressed at all, and / or cases where the polypeptide has no activity even if the polynucleotide is expressed. The above "intrinsic activity" refers to the activity of a specific polypeptide originally possessed by the parent strain, wild type, or unmodified microorganism before the change in trait when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with "activity before modification." The term "weakening, inactivation, deficiency, reduction, downregulation, deterioration, attenuation" of the activity of a polypeptide relative to its intrinsic activity means that the activity of a particular polypeptide is lowered compared to the activity that the parent strain or unmodified microorganism originally had prior to the transformation.
[0101] Attenuation of the activity of such polypeptides can be accomplished by any method known in the art, including but not limited to, and can be achieved by application of various methods well known in the art (e.g., Nakashima N et al., Bacterial cellular engineering by genome editing and gene silencing. Int J Mol Sci. 2014;15(2):2773-2793, Sambrook et al. Molecular Cloning 2012, etc.).
[0102]
[0103] Specifically, the weakening of the activity of the polypeptide of the present application is
[0104] 1) Deletion of all or part of a gene encoding a polypeptide;
[0105] 2) Modification of the expression control region (or expression control sequence) so as to reduce the expression of the gene encoding the polypeptide;
[0106] 3) Modification of the amino acid sequence constituting the polypeptide (e.g., deletion / substitution / addition of one or more amino acids in the amino acid sequence) so as to eliminate or weaken the activity of the polypeptide;
[0107] 4) Modification of the gene sequence encoding the polypeptide such that the activity of the polypeptide is eliminated or weakened (e.g., deletion / substitution / addition of one or more nucleotide bases in the nucleotide sequence of the polypeptide gene such that the polypeptide is modified such that the activity of the polypeptide is eliminated or weakened);
[0108] 5) Modification of the base sequence encoding the initiation codon, Shine-Dalgarno sequence or 5'-UTR region of a gene transcript encoding a polypeptide;
[0109] 6) Introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to a transcript of the gene encoding the polypeptide;
[0110] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence to the front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure to which ribosome attachment is impossible;
[0111] 8) Addition of a promoter that is transcribed in the opposite direction to the 3' end of the open reading frame (ORF) of the gene sequence encoding the polypeptide (Reverse transcription engineering, RTE); or
[0112] 9) It may be a combination of two or more of the above 1) to 8), but is not particularly limited thereto.
[0113] for example,
[0114] The above 1) deletion of part or all of the gene encoding the polypeptide may be the removal of the entire polynucleotide encoding the endogenous target polypeptide in the chromosome, replacement with a polynucleotide having some nucleotides deleted, or replacement with a marker gene.
[0115] The above 2) modification of the expression control region (or expression control sequence) may be a mutation in the expression control region (or expression control sequence) by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, or replacement with a sequence having weaker activity. The expression control region includes, but is not limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation.
[0116] The modification of the amino acid sequence or polynucleotide sequence of the above 3) and 4) may be, but is not limited to, a mutation in the sequence of the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide, such as deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so as to weaken the activity of the polypeptide, or replacement with an amino acid sequence or polynucleotide sequence improved to have weaker activity, or an amino acid sequence or polynucleotide sequence improved to have no activity. For example, the expression of the gene may be inhibited or weakened by introducing a mutation in the polynucleotide sequence to form a stop codon, but is not limited thereto.
[0117] The above 5) modification of the base sequence encoding the initiation codon or 5'-UTR region of the gene transcript encoding the polypeptide may be, for example, a substitution with a base sequence encoding another initiation codon having a lower polypeptide expression rate than the endogenous initiation codon, but is not limited thereto.
[0118] The introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to the transcript of the gene encoding the polypeptide 6) above can be described, for example, with reference to the literature [Weintraub, H. et al., Antisense-RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986].
[0119] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence in front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure to which ribosome attachment is impossible may render mRNA translation impossible or slow it down.
[0120] In addition, the addition of a promoter transcribed in the opposite direction to the 3' end of the ORF (open reading frame) of the gene sequence encoding the polypeptide (Reverse transcription engineering, RTE) may weaken the activity by creating an antisense nucleotide complementary to the transcript of the gene encoding the polypeptide.
[0121]
[0122] Another aspect of the present application provides a method for producing L-tryptophan, comprising the step of culturing a Corynebacterium genus microorganism producing L-tryptophan into which an exogenous glnA protein or a polynucleotide encoding the same has been introduced in a medium.
[0123] The method for producing L-tryptophan of the present application may include a step of culturing a microorganism in which a foreign glnA protein or a glnA gene encoding the foreign glnA protein is enhanced, or a microorganism genetically modified to further enhance a foreign glnA protein or a glnA gene encoding the foreign glnA protein, in a medium, as described above.
[0124] The above exogenous glnA protein may have increased glutamine synthetase activity compared to a wild-type Corynebacterium microorganism. Alternatively, the above exogenous glnA protein may not be endogenously expressed in a wild-type Corynebacterium microorganism.
[0125]
[0126] In this application, the term "cultivation" refers to growing the microorganism of this application under appropriately controlled environmental conditions. The culturing process of this application can be performed using any suitable medium and culture conditions known in the art. This culturing process can be easily adjusted and used by those skilled in the art depending on the selected microorganism. Specifically, the culturing process may be batch, continuous, and / or fed-batch, but is not limited thereto.
[0127] In this application, the term "medium" refers to a material containing nutrients as a main component necessary for culturing the microorganism of this application, and supplies nutrients and growth factors, including water, which is essential for survival and growth. Specifically, the medium and other culture conditions used for culturing the microorganism of this application may be any medium used for culturing general microorganisms without particular limitation, but the microorganism of this application may be cultured under aerobic conditions while controlling temperature, pH, etc. in a general medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid, and / or vitamin.
[0128] Specifically, culture media for microorganisms of the genus Corynebacterium can be found in the literature ["Manual of Methods for General Bacteriology" by the American Society for Bacteriology (Washington DC, USA, 1981)].
[0129] In the present application, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc.; organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc. In addition, natural organic nutrients such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sugarcane bagasse, and corn steep liquor may be used, and specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted to reducing sugar) may be used, and other appropriate amounts of carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.
[0130] The nitrogen source may include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; organic nitrogen sources such as amino acids such as glutamic acid, methionine, glutamine, etc.; peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its decomposition product, defatted soybean cake or its decomposition product, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.
[0131] The above-mentioned components may include potassium phosphate monobasic, potassium phosphate dibasic, or their corresponding sodium-containing salts. Inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. In addition, amino acids, vitamins, and / or suitable precursors may be included. These components or precursors may be added to the medium in batch or continuous manner, but are not limited thereto.
[0132] In addition, during the cultivation of the microorganism of the present application, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. may be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during the cultivation, foaming may be suppressed by using an antifoaming agent such as fatty acid polyglycol ester. In addition, to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas may be injected into the medium, or to maintain the anaerobic and microaerobic state, nitrogen, hydrogen, or carbon dioxide gas may be injected without gas injection, but is not limited thereto.
[0133] In the culture of the present application, the culture temperature can be maintained at 20 to 45°C, specifically 25 to 40°C, and the culture can be performed for about 10 to 160 hours, but is not limited thereto.
[0134] L-tryptophan produced by the culture of the present invention may be secreted into the medium or remain within the cells.
[0135]
[0136] The method for producing L-tryptophan of the present application may additionally include a step of preparing a microorganism of the present application, a step of preparing a medium for culturing the microorganism, or a combination thereof (in any order), for example, before the culturing step.
[0137] The L-tryptophan production method of the present application may further include a step of recovering L-tryptophan from the culture medium (medium in which culture is performed) or the cultured microorganism. The recovering step may be additionally included after the culturing step.
[0138] The above recovery may be performed by collecting the target L-tryptophan using a suitable method known in the art according to the culture method of the microorganism of the present application, for example, a batch, continuous or fed-batch culture method. For example, various chromatographies such as centrifugation, filtration, treatment with a crystallized protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC or a combination thereof may be used, and the target L-tryptophan may be recovered from the medium or microorganism using a suitable method known in the art.
[0139] Additionally, the L-tryptophan production method of the present application may additionally include a purification step. The purification may be performed using any suitable method known in the art. In one example, if the L-tryptophan production method of the present application includes both a recovery step and a purification step, the recovery step and the purification step may be performed sequentially or discontinuously, regardless of the order, or may be performed simultaneously or integrated into a single step, but is not limited thereto.
[0140] In the method of the present application, the foreign glnA protein, polynucleotide, vector, microorganism, etc. are as described in the other aspects above.
[0141]
[0142] Another aspect of the present application provides a composition for producing L-tryptophan, comprising a Corynebacterium microorganism into which an exogenous glnA protein or a polynucleotide encoding the same has been introduced; a medium in which the same has been cultured; or a combination thereof.
[0143]
[0144] The composition of the present application may further comprise any suitable excipient commonly used in compositions for producing L-tryptophan, and such excipients may be, for example, but are not limited to, preservatives, wetting agents, dispersing agents, suspending agents, buffering agents, stabilizers, or isotonic agents.
[0145]
[0146] Another aspect of the present application provides a method for producing a microorganism of the genus Corynebacterium producing L-tryptophan, comprising the step of introducing a foreign glnA protein or a polynucleotide encoding the same.
[0147] The above-mentioned foreign glnA protein, the polynucleotide encoding it, and the microorganism are as described above.
[0148]
[0149] The above manufacturing method may include a step of modifying a microorganism such that the microorganism has increased glutamine synthetase activity compared to its intrinsic activity. This involves introducing an exogenous glnA protein into a microorganism of the genus Corynebacterium.
[0150]
[0151] Another aspect of the present application provides a use of a microorganism of the genus Corynebacterium, into which an exogenous glnA protein or a polynucleotide encoding the same has been introduced, for producing L-tryptophan.
[0152]
[0153] The above-mentioned foreign glnA protein, Corynebacterium genus microorganisms, etc. are as described in the other aspects above.
[0154]
[0155] The present application will be described in more detail below through examples. However, the following examples are merely preferred embodiments intended to illustrate the present application and are therefore not intended to limit the scope of the present application. Furthermore, technical details not described herein can be readily understood and implemented by those skilled in the technical field of the present application or similar fields.
[0156]
[0157] Example 1: Identification and screening of a gene encoding glutamine synthetase (glnA).
[0158] Using the amino acid sequence of the glnA protein from Corynebacterium glutamicum as a query sequence, PSI-BLAST was performed against the NCBI and Kegg databases to identify candidate proteins predicted to have glutamine biosynthetic activity from glutamic acid and ammonia, their encoding genes, and microorganisms harboring them. Eleven candidate proteins were selected, taking into account the biosafety level applicable to amino acid production and the availability of the produced amino acids, as shown in Table 1 below.
[0159]
[0160] No. Strain name Protein registration number Genome registration number Bacterial safety level 1 Aureibacillus halotolerans WP_133580410.1NZ_SNYJ01000007.112 Caryophanon tenue WP_066543527.1NZ_MASJ01000003.113 Peribacillus simplex WP_063236399.1NZ_CP017704.114 Carnobacterium divergens WP_119907903.1NZ_CP016843.115 Bacillus gobiensis WP_053602893.1NZ_CP012600.116 Carnobacterium inhibens WP_023178082.1NC_022606.117 Carnobacterium inersWP_085560080.1NZ_FOAH01000008.118Lactiplantibacillus paraplantarumWP_003640333.1NZ_CP028423.119Sulfolobus acidocaldariusWP_011278306.1NC_007181.1110Petroclostridium xylanilyticumWP_094551848.1NZ_NPML01000029.1111Bacillus subtilisWP_003231737.1NZ_JNCM01000035.11
[0161]
[0162] Example 2: Construction of plasmids for gene insertion
[0163] A plasmid was constructed using pDCM2 (US 2023-0134555 A1) for insertion of genes into the Corynebacterium chromosome.
[0164] Using the wild-type Corynebacterium glutamicum ATCC13869 chromosomal DNA as a template, the upstream region where homologous recombination occurs on the chromosome was amplified using the primer pairs of SEQ ID NO: 25 and SEQ ID NO: 26, and the downstream region was amplified using the primer pairs of SEQ ID NO: 27 and SEQ ID NO: 28, and each gene fragment was obtained.
[0165] Polymerase is Solg TM Pfu-X DNA polymerase was used, and PCR amplification was performed under the following conditions: denaturation at 95°C for 4 minutes, denaturation at 95°C for 30 seconds, annealing at 60°C for 30 seconds, polymerization at 72°C for 50 seconds, and then 27 cycles of polymerization at 72°C for 5 minutes.
[0166] The primer sequences used here are as shown in Table 2 below.
[0167]
[0168] SEQ ID NO Sequence Name Sequence (5'-> 3') 25HR1 FaacgacggccagtgaattcGCTCGAATGCCTGACTGACA26HR1 RgtttAGTACTaaaccggaagggccAAAGGACGACTTCACGGTTA27HR2 FccggtttAGTACTaaacaggaagagccATTGAGGATGCGAAACTGT28HR2 RtgcatgcctgcaggtcgacGTAATCGAATCACCGGCCAG
[0169]
[0170] The upstream fragment and downstream fragment of the region where homologous recombination on the chromosome occurs obtained through the above process, and the chromosomal transformation vector pDCM2 digested with EcoRI and SalI restriction enzymes were cloned using the Gibson assembly method (DG Gibson et al., NATURE METHODS, VOL.6 NO.5, MAY 2009, NEBuilder HiFi DNA Assembly Master Mix) to obtain a recombinant plasmid. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in the calculated molar number and then storing at 50℃ for 1 hour. The recombinant plasmid constructed above was named pDCM2-△Tn.
[0171]
[0172] Example 3: Production of a Corynebacterium microorganism with an imported glnA gene.
[0173] 3-1: Production of microorganisms containing the glnA gene derived from Aureibacillus halotolerans
[0174] In order to insert the glnA gene derived from A. halotolerans selected in the above Example 1 into the genomic DNA of Corynebacterium glutamicum, the glnA gene of the A. halotolerans strain synthesized using the gene synthesis service of Bynix Co., Ltd. as a template was used to perform PCR using the primer pairs of SEQ ID NO: 29 and SEQ ID NO: 30 to amplify the glnA gene derived from A. halotolerans (NZ_SNYJ01000007.1, SEQ ID NO: 2). The polymerase was Solg TM Pfu-X DNA polymerase was used, and PCR amplification was performed under the following conditions: denaturation at 95°C for 2 minutes, denaturation at 95°C for 20 seconds, annealing at 60°C for 40 seconds, polymerization at 72°C for 1 minute, repeated 27 times, and then polymerization reaction at 72°C for 5 minutes.
[0175] In addition, to secure the PlysCm1 promoter (US 2023-0134555 A1) to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA (US 2023-0134555 A1) as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 32. The polymerase was Solg TM Pfu-X DNA polymerase was used, and PCR amplification was performed under the following conditions: denaturation at 95°C for 2 minutes, denaturation at 95°C for 20 seconds, annealing at 60°C for 40 seconds, polymerization at 72°C for 30 seconds (27 cycles), and then polymerization at 72°C for 5 minutes.
[0176] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the glnA gene fragment derived from A. halotolerans, and the pDCM2-△Tn of Example 2, which was digested with the ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar amount and then storing it at 50°C for 1 hour. The recombinant plasmid containing the glnA gene derived from A. halotolerans constructed above was named pDCM2-△Tn:: PlysCm1-glnA(A.ht).
[0177] The constructed pDCM2-△Tn::PlysCm1-glnA(A.ht) plasmid was transformed into the L-tryptophan-producing strain CM05-9157 (US 2023-0134555 A1) by electroporation (Appl. Microbiol. Biotechnol. (1999) 52:541-545), and a strain in which one copy of PlysCm1-glnA(A.ht) was introduced between transposon genes on the chromosome was obtained through a second crossing-over process. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, and by genome sequencing. The strain into which PlysCm1-glnA(A.ht) obtained above was introduced was named CM05-9883.
[0178]
[0179] 3-2: Production of microorganisms containing the glnA gene derived from Caryophanon tenue
[0180] In order to insert the C. tenue-derived gllnA gene selected in the above Example 1 into the Corynebacterium glutamicum genomic DNA, PCR was performed using the primer pair of SEQ ID NO: 35 and SEQ ID NO: 36 using the C. tenue strain gllnA gene synthesized using the gene synthesis service of Bynix Co., Ltd. as a template, using the method of Example 3-1, to amplify the C. tenue-derived gllnA gene (NZ_MASJ01000003.1, SEQ ID NO: 4).
[0181] In addition, in order to secure the PlysCm1 promoter to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 37 by the method of Example 3-1.
[0182] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the C. tenue-derived glnA gene fragment, and the pDCM2-△Tn of Example 2, which had been digested with the ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar amount and then storing it at 50°C for 1 hour. The recombinant plasmid containing the C. tenue-derived glnA gene constructed above was named pDCM2-△Tn::PlysCm1-glnA(C.te).
[0183] The constructed pDCM2-△Tn::PlysCm1-glnA(C.te) plasmid was transformed into the tryptophan-producing strain CM05-9157 by electroporation, and a second crossover process was performed to obtain a strain in which one copy of PlysCm1-glnA(C.te) was introduced between transposon genes on the chromosome. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, respectively, and by genome sequencing. The strain into which PlysCm1-glnA(C.te) was introduced obtained above was named CM05-9885.
[0184]
[0185] 3-3: Production of microorganisms containing the glnA gene derived from Peribacillus simplex
[0186] In order to insert the P. simplex-derived gllnA gene selected in the above Example 1 into the Corynebacterium glutamicum genomic DNA, PCR was performed using the primer pair of SEQ ID NO: 38 and SEQ ID NO: 39 using the glnA gene of the synthesized P. simplex strain as a template using the gene synthesis service of Bynix Co., Ltd., and the P. simplex-derived gllnA gene (NZ_CP017704.1, SEQ ID NO: 6) was amplified using the method of Example 3-1.
[0187] In addition, in order to secure the PlysCm1 promoter to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 40 by the method of Example 3-1.
[0188] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the P. simplex-derived glnA gene fragment, and the pDCM2-△Tn of Example 2, which had been digested with the ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar amount and then storing it at 50°C for 1 hour. The recombinant plasmid containing the P. simplex-derived glnA gene constructed above was named pDCM2-△Tn::PlysCm1-glnA(P.si).
[0189] The constructed pDCM2-△Tn::PlysCm1-glnA(P.si) plasmid was transformed into the tryptophan-producing strain CM05-9157 by electroporation, and a second crossover process was performed to obtain a strain in which one copy of PlysCm1-glnA(P.si) was introduced between transposon genes on the chromosome. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, respectively, and by genome sequencing. The strain into which PlysCm1-glnA(P.si) was introduced obtained above was named CM05-9879.
[0190]
[0191] 3-4: Production of microorganisms containing the glnA gene derived from Carnobacterium divergens
[0192] In order to insert the glnA gene derived from C. divergens selected in the above Example 1 into the genomic DNA of Corynebacterium glutamicum, PCR was performed using the glnA gene of the C. divergens strain synthesized using the gene synthesis service of Bynix Co., Ltd. as a template and the primer pair of SEQ ID NO: 41 and SEQ ID NO: 42 using the method of Example 3-1 to amplify the glnA gene derived from C. divergens (NZ_CP016843.1, SEQ ID NO: 8).
[0193] In addition, in order to secure the PlysCm1 promoter to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 43 by the method of Example 3-1.
[0194] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the glnA gene fragment derived from C. divergens, and the pDCM2-△Tn of Example 2, which was digested with the ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar amount and then storing it at 50°C for 1 hour. The recombinant plasmid containing the glnA gene derived from C. divergens constructed above was named pDCM2-△Tn::PlysCm1-glnA(C.di).
[0195] The constructed pDCM2-△Tn::PlysCm1-glnA(C.di) plasmid was transformed into the tryptophan-producing strain CM05-9157 by electroporation, and a second crossover process was performed to obtain a strain in which one copy of PlysCm1-glnA(C.di) was introduced between transposon genes on the chromosome. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, respectively, and by genome sequencing. The strain into which PlysCm1-glnA(C.di) was introduced obtained above was named CM05-9877.
[0196]
[0197] 3-5: Production of microorganisms containing the glnA gene derived from Bacillus gobiensis
[0198] In order to insert the B. gobiensis-derived glnA gene selected in the above Example 1 into the Corynebacterium glutamicum genomic DNA, PCR was performed using the primer pair of SEQ ID NO: 44 and SEQ ID NO: 45 using the B. gobiensis strain glnA gene synthesized using the gene synthesis service of Bynix Co., Ltd. as a template, using the method of Example 3-1, to amplify the B. gobiensis-derived glnA gene (NZ_CP012600.1, SEQ ID NO: 10).
[0199] In addition, in order to secure the PlysCm1 promoter to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 46 by the method of Example 3-1.
[0200] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the B. gobiensis-derived glnA gene fragment, and the pDCM2-△Tn of Example 2, which was digested with the ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar amount and then storing it at 50°C for 1 hour. The recombinant plasmid containing the B. gobiensis-derived glnA gene constructed above was named pDCM2-△Tn::PlysCm1-glnA(B.go).
[0201] The constructed pDCM2-△Tn::PlysCm1-glnA(B.go) plasmid was transformed into the tryptophan-producing strain CM05-9157 by electroporation, and a second crossover process was performed to obtain a strain in which one copy of PlysCm1-glnA(B.go) was introduced between transposon genes on the chromosome. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, and by genome sequencing. The strain into which PlysCm1-glnA(B.go) was introduced as obtained above was designated CM05-9879.
[0202]
[0203] 3-6: Production of microorganisms containing the glnA gene derived from Carnobacterium inhibens
[0204] In order to insert the C. inhibens-derived gllnA gene selected in the above Example 1 into the Corynebacterium glutamicum genomic DNA, the glnA gene of the C. inhibens strain synthesized using the gene synthesis service of Bynix Co., Ltd. as a template was used, and PCR was performed using the primer pair of SEQ ID NO: 47 and SEQ ID NO: 48 using the method of Example 3-1 to amplify the C. inhibens-derived gllnA gene (NC_022606.1, SEQ ID NO: 12).
[0205] In addition, in order to secure the PlysCm1 promoter to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 49 by the method of Example 3-1.
[0206] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the glnA gene fragment derived from C. inhibens, and the pDCM2-△Tn of Example 2, which was digested with the ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar amount and then storing it at 50°C for 1 hour. The recombinant plasmid containing the glnA gene derived from C. inhibens constructed above was named pDCM2-△Tn::PlysCm1-glnA(C.in).
[0207] The constructed pDCM2-△Tn::PlysCm1-glnA(C.in) plasmid was transformed into the tryptophan-producing strain CM05-9157 by electroporation, and a second crossover process was performed to obtain a strain in which one copy of PlysCm1-glnA(C.in) was introduced between transposon genes on the chromosome. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, respectively, and by genome sequencing. The strain into which PlysCm1-glnA(C.in) was introduced was named CM05-9878.
[0208]
[0209] 3-7: Production of microorganisms containing the glnA gene derived from Carnobacterium iners
[0210] In order to insert the C. iners-derived gllnA gene selected in the above Example 1 into the Corynebacterium glutamicum genomic DNA, PCR was performed using the primer pair of SEQ ID NO: 50 and SEQ ID NO: 51 using the glnA gene of the C. iners strain synthesized using the gene synthesis service of Bynix Co., Ltd. as a template, and the C. iners-derived gllnA gene (NZ_FOAH01000008.1, SEQ ID NO: 14) was amplified using the method of Example 3-1.
[0211] In addition, in order to secure the PlysCm1 promoter to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 52 by the method of Example 3-1.
[0212] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the C. iners-derived glnA gene fragment, and the pDCM2-△Tn of Example 2, which had been digested with the ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar amount and then storing it at 50°C for 1 hour. The recombinant plasmid containing the C. iners-derived glnA gene constructed above was named pDCM2-△Tn::PlysCm1-glnA(C.ar).
[0213] The constructed pDCM2-△Tn::PlysCm1-glnA(C.ar) plasmid was transformed into the tryptophan-producing strain CM05-9157 by electroporation, and a second crossover process was performed to obtain a strain in which one copy of PlysCm1-glnA(C.ar) was introduced between transposon genes on the chromosome. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, and by genome sequencing. The strain into which PlysCm1-glnA(C.ar) was introduced obtained above was named CM05-9884.
[0214]
[0215] 3-8: Production of microorganisms containing the glnA gene derived from Lactiplantibacillus paraplantarum
[0216] In order to insert the glnA gene derived from L. paraplantarum selected in the above Example 1 into the genomic DNA of Corynebacterium glutamicum, the glnA gene of the L. paraplantarum strain synthesized using the gene synthesis service of Bynix Co., Ltd. as a template was used to perform PCR using the primer pair of SEQ ID NO: 53 and SEQ ID NO: 54 using the method of Example 3-1 to amplify the glnA gene derived from L. paraplantarum (NZ_CP028423.1, SEQ ID NO: 16).
[0217] In addition, in order to secure the PlysCm1 promoter to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 55 by the method of Example 3-1.
[0218] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the glnA gene fragment derived from L. paraplantarum, and the pDCM2-△Tn of Example 2, which was digested with the ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar amount and then storing it at 50°C for 1 hour. The recombinant plasmid containing the glnA gene derived from L. paraplantarum constructed above was named pDCM2-△Tn::PlysCm1-glnA(L.pa).
[0219] The constructed pDCM2-△Tn::PlysCm1-glnA(L.pa) plasmid was transformed into the tryptophan-producing strain CM05-9157 by electroporation, and a second crossover process was performed to obtain a strain in which one copy of PlysCm1-glnA(L.pa) was introduced between transposon genes on the chromosome. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, respectively, and by genome sequencing. The strain into which PlysCm1-glnA(L.pa) was introduced obtained above was named CM05-9880.
[0220]
[0221] 3-9: Production of microorganisms containing the glnA gene derived from Sulfolobus acidocaldarius
[0222] In order to insert the glnA gene derived from S. acidocaldarius selected in the above Example 1 into the genomic DNA of Corynebacterium glutamicum, the glnA gene of the S. acidocaldarius strain synthesized using the gene synthesis service of Bynix Co., Ltd. as a template was used, and PCR was performed using the primer pair of SEQ ID NO: 56 and SEQ ID NO: 57 using the method of Example 3-1 to amplify the glnA gene derived from S. acidocaldarius (NC_007181.1, SEQ ID NO: 18).
[0223] In addition, in order to secure the PlysCm1 promoter to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 58 by the method of Example 3-1.
[0224] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the glnA gene fragment derived from S. acidocaldarius, and the pDCM2-△Tn of Example 2, which was digested with the ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar amount and then storing it at 50°C for 1 hour. The recombinant plasmid containing the glnA gene derived from S. acidocaldarius constructed above was named pDCM2-△Tn::PlysCm1-glnA(S.ac).
[0225] The constructed pDCM2-△Tn::PlysCm1-glnA(S.ac) plasmid was transformed into the tryptophan-producing strain CM05-9157 by electroporation, and a second crossover process was performed to obtain a strain in which one copy of PlysCm1-glnA(S.ac) was introduced between transposon genes on the chromosome. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, and by genome sequencing. The strain into which PlysCm1-glnA(S.ac) was introduced obtained above was named CM05-9882.
[0226]
[0227] 3-10: Production of microorganisms containing glnA gene derived from Petroclostridium xylanilyticum
[0228] In order to insert the glnA gene derived from P. xylanilyticum selected in the above Example 1 into the genomic DNA of Corynebacterium glutamicum, the glnA gene of the P. xylanilyticum strain synthesized using the gene synthesis service of Bynix Co., Ltd. as a template was used, and PCR was performed using the primer pair of SEQ ID NO: 59 and SEQ ID NO: 60 using the method of Example 3-1 to amplify the glnA gene derived from P. xylanilyticum (NZ_NPML01000029.1, SEQ ID NO: 20).
[0229] In addition, in order to secure the PlysCm1 promoter to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 61 by the method of Example 3-1.
[0230] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the glnA gene fragment derived from P. xylanilyticum, and the pDCM2-△Tn of Example 2, which was digested with the ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar amount and then storing it at 50°C for 1 hour. The recombinant plasmid containing the glnA gene derived from P. xylanilyticum constructed above was named pDCM2-△Tn::PlysCm1-glnA(P.xy).
[0231] The constructed pDCM2-△Tn::PlysCm1-glnA(P.xy) plasmid was transformed into the tryptophan-producing strain CM05-9157 by electroporation, and a second crossover process was performed to obtain a strain in which one copy of PlysCm1-glnA(P.xy) was introduced between transposon genes on the chromosome. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, and by genome sequencing. The strain into which PlysCm1-glnA(P.xy) was introduced obtained above was named CM05-9886.
[0232]
[0233] 3-11: Production of microorganisms containing the glnA gene derived from Bacillus subtilis
[0234] In order to insert the B. subtilis-derived glnA gene selected in the above Example 1 into the Corynebacterium glutamicum genomic DNA, PCR was performed using the primer pair of SEQ ID NO: 62 and SEQ ID NO: 63 using the B. subtilis strain glnA gene synthesized using the gene synthesis service of Bynix Co., Ltd. as a template, using the method of Example 3-1, to amplify the B. subtilis-derived glnA gene (NZ_JNCM01000035.1, SEQ ID NO: 22).
[0235] In addition, in order to secure the PlysCm1 promoter to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 64 by the method of Example 3-1.
[0236] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the B. subtilis-derived glnA gene fragment, and the pDCM2-△Tn of Example 2, which had been digested with the ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar number and then storing it at 50°C for 1 hour. The recombinant plasmid containing the B. subtilis-derived glnA gene constructed above was named pDCM2-△Tn::PlysCm1-glnA(B.su).
[0237] The constructed pDCM2-△Tn::PlysCm1-glnA(B.su) plasmid was transformed into the tryptophan-producing strain CM05-9157 by electroporation, and a second crossover process was performed to obtain a strain in which one copy of PlysCm1-glnA(B.su) was introduced between transposon genes on the chromosome. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, and by genome sequencing. The strain into which PlysCm1-glnA(B.su) was introduced obtained above was named CM05-9550.
[0238] The primer sequences used in Examples 3-1 to 3-11 are as shown in Table 3 below.
[0239]
[0240] 서열번호서열명서열(5'-> 3')29glnA(A.ht)-FgaaaggtgcacacatATGGGTTCTAAGTACACGAG30glnA(A.ht)-RCTCTTCCTGTTTAGTTTAGTAAAGGGTAAGGTACTGC31PlysCm1-FC CCTTCCGGTTTAGTGCTCCTTAGGGAGCCATCTTTTG32PlysCm1(A.ht)-RGTACTTAGAACCCATatgtgtgcacctttcgatct33Confirm-PlysCm1-glnA-FTTT ACCTCCCACAAGTCC34Confirm-PlysCm1-glnA-RAAGAATCTCCCTGCCAAA35glnA(C.te)-FaaggtgcacacatATGGGTAAATACAAAAGACG36glnA(C.t e)-RCTCTTCCTGTTTAGTTTAATACATTTTTAAATATTGGTCACGTTCC37PlysCm1(C.te)-RTGTGTATTTACCCATgtgtgcaccttcgatct38glnA(P.si)-F AAAGGTGCACAcatATGGCAAAGTTCACACGTGAA39glnA(P.si)-RCTCTTCCTGTTTAGTTTAATACATTGACATATATTGTTCGCG40PlysCm1(P.si)-RTGTGAACT TTGCCATatgtgtgcaccttcgatct41glnA(C.di)-FaaggtgcacacatATGCCAGAATTTACAAGAGAAC42glnA(C.di)-RCTCTTCCTGTTTAGTTTAGTATAACT CTAAATATTGTTCTCT43PlysCm1(C.di)-RTGTAAATTCTGGCATatgtgtgcacctttcgatct44glnA(B.go)-FggtgcacacatATGGCAAAGTATACTAGAGAAGA T45glnA(B.go)-RCTCTTCCTGTTTAGTTTAAACTGAGTTAAATATTGATCGCGT46PlysCm1(B.go)-RAGTATACTTTGCCATatgtgtgcacctttcgatct47glnA (C.in)-FATGAAAAATTTACAAGGAAAGAAATCGAAATAAGTGC48glnA (C.in)-RCTCTTCCTGTTTAGTTTAataTAAGGTTAGATATTTTTCTTTTTCCCATTCAGAAACTTG49PlysCm1((C.in)-RTGTAAATTTTTTCATatgtgtgcacctttcgatct50glnA(C.ar)-FATGAAAAATTTTACTAGAGAAGAAATCGTAACAAG51glnA(C.ar)-RCTCTTCCTGTTTAGTTTAATAAAGAGTCATATACTTTTCTTGTTCCC52PlysCm1(C.ar)-RAGTAAAATTTTTCATatgtgtgcacctttcgatct53glnA(L.pa)-FgaaaggtgcacacatATGGCAAAACAGTCCTATTC54glnA(L.pa)-RCTCTTCCTGTTTAGTTTAATACAGTTCCATGTACTGATCACGT55PlysCm1(L.pa)-RGGACTGTTTTGCCATatgtgtgcacctttcgatct56glnA(S.ac)-FaaggtgcacacatATGCCAGGACTTCCAAAAAATG57glnA(S.ac)-RCTCTTCCTGTTTAGTTTAAGAATCTAGATACTGATATATTTCCATAGGATGTGG58PlysCm1(S.ac)-RTGGAAGTCCTGGCATatgtgtgcacctttcgatct59glnA(P.xy)-FgaaaggtgcacacatATGCCTAACTATACCAGGGA60glnA(P.xy)-RCTCTTCCTGTTTAGTTTAATATCTGGTGAGATACTGGTCG61PlysCm1(P.xy)-RGGTATAGTTAGGCATatgtgtgcacctttcgatct62glnA(B.su)-FGAAAGGTGCACACATATGGCAAAGTACACTAGAGAAG63glnA(B.su)-RCTCTTCCTGTTTAGTTTAATACTGAGACATATACTGTTCG64PlysCm1(B.su)-RAGTGTACTTTGCCATATGTGTGCACCTTTCGATCTA.
[0241]
[0242] Comparative example: Production of a Corynebacterium microorganism with the glnA gene derived from Corynebacterium glutamicum.
[0243] As a comparative example, the glnA gene derived from wild-type Corynebacterium glutamicum ATCC 13869 was inserted into Corynebacterium glutamicum genomic DNA, and the base sequence of the start codon was replaced with ATG to increase the expression amount of the glnA protein. First, PCR was performed using the genomic DNA of the wild-type Corynebacterium glutamicum ATCC 13869 strain as a template and the primer pair of SEQ ID NO: 65 and SEQ ID NO: 66 by the method of Example 3-1 to amplify the glnA gene (SEQ ID NO: 23) derived from wild-type Corynebacterium glutamicum ATCC 13869.
[0244] In addition, in order to secure the PlysCm1 promoter to enhance the activity of the glnA protein, PCR was performed using pDCM2-Tn::PlysCm1_pheA as a template and the primer pair of SEQ ID NO: 31 and SEQ ID NO: 67 by the method of Example 3-1.
[0245] A recombinant plasmid was obtained by cloning the amplified PlysCm1 promoter region, the glnA gene fragment derived from wild-type Corynebacterium glutamicum ATCC 13869, and pDCM2-βTn of Example 2, which was digested with ScaI restriction enzyme, using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in a calculated molar amount and then storing at 50°C for 1 hour. The recombinant plasmid containing the glnA gene derived from wild-type Corynebacterium glutamicum ATCC 13869 constructed above was named pDCM2-βTn::PlysCm1-glnA(C.gl).
[0246] The constructed pDCM2-βTn::PlysCm1-glnA(C.gl) plasmid was transformed into the tryptophan-producing strain CM05-9157 by electroporation, and a second crossover process was performed to obtain a strain in which one copy of PlysCm1-glnA(C.gl) was introduced between transposon genes on the chromosome. The genetic manipulation was confirmed by PCR using the primer pair of SEQ ID NOs: 33 and 34, which can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, respectively, and by genome sequencing. The strain into which PlysCm1-glnA(C.gl) was introduced as obtained above was named CM05-9548.
[0247] The primer sequences used in the above comparative examples are as shown in Table 4 below.
[0248]
[0249] SEQ ID NO: Sequence Name Sequence (5'-> 3')65glnA(C.gl)-FGAAAGGTGCACACATATGGCGTTTGAAACCCCGGA66glnA(C.gl)-RCTCTTCCTGTTTAGTTTAGCAGTCGAAGTACAATTCGAA67PlysCm1(C.gl)-RGGTTTCAAACGCCATATGTGTGCACCTTTCGATCTACG
[0250]
[0251] Example 4: Confirmation of L-tryptophan production ability of Corynebacterium microorganisms with foreign glnA genes introduced.
[0252] In order to confirm the L-tryptophan production ability of the strains into which the foreign glnA gene was introduced, produced in Examples 3-1 to 3-11, the parent strain CM05-9157 as a control group, and the wild-type Corynebacterium glutamicum ATCC 13869-derived glnA gene-introduced CM05-9548 strain, the strains were cultured using the following method.
[0253] Each strain was inoculated into a 250 ml corner-baffle flask containing 25 ml of seed medium and cultured at 30°C for 20 hours with shaking at 200 rpm to obtain a seed culture. 1 ml of the seed culture was inoculated into a 250 ml corner-baffle flask containing 25 ml of production medium and cultured at 30°C for 24 hours with shaking at 200 rpm. After completion of the culture, the production amount of L-tryptophan was measured by HPLC and the results are shown in Table 5 below.
[0254]
[0255] <Jongbaeji>
[0256] Glucose 20g, peptone 10g, yeast extract 5g, urea 1.5g, KH2PO4 4g, K2HPO4 8g, MgSO4 7H2O 0.5g, biotin 100㎍, thiamine HCl 1000㎍, calcium-pantothenic acid 2000㎍, nicotinamide 2000㎍, pH 7.0 (based on 1 liter of distilled water)
[0257]
[0258] <Production medium>
[0259] Glucose 30 g, (NH4)2SO4 15 g, MgSO4 7H2O 1.2 g, KH2PO4 1 g, yeast extract 5 g, biotin 900 μg, thiamine hydrochloride 4500 μg, calcium-pantothenic acid 4500 μg, CaCO3 30 g, pH 7.0 (based on 1 liter of distilled water).
[0260]
[0261] Strain name Origin of the introduced glnA gene OD562 L-tryptophan production (g / L) L-tryptophan yield (*100 g / g, %) CM05-9157-56.91.896.37 CM05-9548 Corynebacterium glutamicum 571.886.36 CM05-9877 Carnobacterium divergens 56.51.916.45 CM05-9878 Carnobacterium inhibens 56.51.96.4 CM05-9879 Peribacillus simplex 52.52.177.3 CM05-9880 Lactiplantibacillus paraplantarum 57.21.775.96 CM05-9881 Bacillus gobiensis57.41.745.86CM05-9882Sulfolobus acidocaldarius581.645.51CM05-9883Aureibacillus halotolerans51.92.377.93CM05-9884Carnobacterium iners56.81.886.35CM05-9885Caryophanon tenue522.337.77CM05-9886Petroclostridium xylanilyticum57.11.765.9CM05-9550Bacillus subtilis53.11.976.68
[0262]
[0263] As shown in Table 5 above, the tryptophan production of the CM05-9548 strain into which the glnA gene derived from Corynebacterium glutamicum was introduced was 1.88 g / L, which was almost the same as the tryptophan production of the CM05-9157 strain, the parent strain into which the glnA gene was not introduced.
[0264] On the other hand, among the 11 production strains into which the foreign glnA gene was introduced, the CM05-9883 strain into which the glnA gene derived from A. halotolerans was introduced produced a final 2.37 g / L of L-tryptophan in flask culture, which was an approximately 25% improvement in fermentation yield compared to the control strain CM05-9548. The CM05-9885 strain into which the glnA gene derived from C. tenue was introduced produced a final 2.33 g / L of L-tryptophan in flask culture, which was an approximately 23% improvement in fermentation yield compared to the control strain CM05-9548. In addition, P. The CM05-9879 strain, into which the simplex-derived glnA gene was introduced, produced a final L-tryptophan of 2.17 g / L in flask culture, showing an approximately 15% improvement in fermentation yield compared to the control strain, CM05-9548.
[0265] From this, it was confirmed that among the 11 foreign glnA genes, the glnA genes derived from A. halotolerans, C. tenue, and P. simplex specifically increased L-tryptophan production in Corynebacterium glutamicum strains.
[0266]
[0267] From the above description, those skilled in the art will understand that the present application can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of this application should be interpreted to include all changes or modifications derived from the meaning and scope of the following claims and their equivalents, rather than the detailed description above.
Claims
1. A microorganism of the genus Corynebacterium into which a foreign glnA protein or a polynucleotide encoding the same has been introduced.
2. A microorganism according to claim 1, wherein the protein is derived from at least one microorganism selected from the group consisting of Aureibacillus halotolerans, Caryophanon tenue, and Peribacillus simplex.
3. A microorganism according to claim 1, wherein the protein comprises at least one selected from the group consisting of an amino acid sequence of any one of SEQ ID NOs: 1, 3, and 5 or an amino acid sequence having at least 70% sequence identity therewith.
4. In the first paragraph, the microorganism of the genus Corynebacterium has increased L-tryptophan production ability compared to the microorganism of the genus Corynebacterium before transformation.
5. A microorganism according to claim 1, wherein the microorganism of the genus Corynebacterium is Corynebacterium glutamicum.
6. A method for producing L-tryptophan, comprising a step of culturing a microorganism of the genus Corynebacterium into which a foreign glnA protein or a polynucleotide encoding the same has been introduced in a medium.
7. A method according to claim 6, wherein the protein is derived from at least one microorganism selected from the group consisting of Aureibacillus halotolerans, Caryophanon tenue, and Peribacillus simplex.
8. A composition for producing L-tryptophan, comprising a Corynebacterium microorganism into which a foreign glnA protein or a polynucleotide encoding the same has been introduced; a medium in which the same has been cultured; or a combination thereof.
9. A composition according to claim 8, wherein the protein is derived from at least one microorganism selected from the group consisting of Ayureibacillus halotolerans, Caryophanon tenue, and Peribacillus simplex.
